NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
NeurAxis (NYSE American: NRXS) reported strong Q2 2025 financial results, with revenues increasing 46% year-over-year to $894,000. The medical technology company, focused on neuromodulation therapies, achieved significant milestones including FDA clearance for expanded pediatric treatment and secured key academic society guidelines recommendation for their PENFS technology.
Operating expenses decreased 10% year-over-year, while operating loss improved by 22%. The company maintained a cash balance of $6 million, bolstered by a $5 million equity financing round. NeurAxis expanded its covered lives to 53 million and received a new Category I CPT code for PENFS procedures, effective January 2026. The company expects to achieve breakeven in 2026.
NeurAxis (NYSE American: NRXS) ha riportato solidi risultati finanziari nel Q2 2025, con ricavi in aumento del 46% su base annua a $894.000. L'azienda di tecnologia medica, focalizzata sulle terapie di neuromodulazione, ha raggiunto traguardi rilevanti, incluso il nulla osta della FDA per l'ampliamento del trattamento pediatrico e una raccomandazione nelle linee guida di società accademiche per la sua tecnologia PENFS.
Le spese operative sono diminuite del 10% su base annua, mentre la perdita operativa si è ridotta del 22%. La società manteneva una liquidità di $6 milioni, rafforzata da un aumento di capitale di $5 milioni. NeurAxis ha esteso la copertura a 53 milioni di persone e ha ricevuto un nuovo codice CPT di Categoria I per le procedure PENFS, operativo da gennaio 2026. L'azienda prevede di raggiungere il pareggio nel 2026.
NeurAxis (NYSE American: NRXS) presentó sólidos resultados financieros en el 2T 2025, con ingresos que aumentaron un 46% interanual hasta $894,000. La compañía de tecnología médica, centrada en terapias de neuromodulación, alcanzó hitos importantes, incluida la autorización de la FDA para la ampliación del tratamiento pediátrico y la recomendación en las directrices de sociedades académicas para su tecnología PENFS.
Los gastos operativos disminuyeron un 10% interanual, mientras que la pérdida operativa se redujo un 22%. La empresa mantenía un saldo de efectivo de $6 millones, reforzado por una ronda de financiación en acciones de $5 millones. NeurAxis amplió su cobertura a 53 millones de personas y obtuvo un nuevo código CPT de Categoría I para procedimientos PENFS, vigente desde enero de 2026. La compañía espera alcanzar el punto de equilibrio en 2026.
NeurAxis (NYSE American: NRXS)는 2025년 2분기 강력한 실적을 발표했으며 매출이 전년 동기 대비 46% 증가해 $894,000를 기록했습니다. 신경조절(neuromodulation) 치료에 주력하는 이 의료기술 회사는 소아 치료 확대에 대한 FDA 승인을 포함한 주요 성과를 달성했으며, 자사 PENFS 기술에 대해 학술단체 지침의 권고도 확보했습니다.
영업비용은 전년 동기 대비 10% 감소했고 영업손실은 22% 개선되었습니다. 회사는 $6백만의 현금 잔고를 유지했으며, $5백만 규모의 주식 자금조달로 이를 보강했습니다. NeurAxis는 보장 대상자를 5,300만명으로 확대했고 PENFS 시술에 대해 2026년 1월부터 효력 발생하는 새로운 카테고리 I CPT 코드를 받았습니다. 회사는 2026년에 손익분기점을 달성할 것으로 예상합니다.
NeurAxis (NYSE American: NRXS) a publié de solides résultats pour le 2e trimestre 2025, avec un chiffre d'affaires en hausse de 46% en glissement annuel à $894,000. La société de technologie médicale, axée sur les thérapies de neuromodulation, a franchi des étapes importantes, notamment l'autorisation de la FDA pour l'élargissement du traitement pédiatrique et l'obtention d'une recommandation dans les directives de sociétés savantes pour sa technologie PENFS.
Les charges d'exploitation ont diminué de 10% en glissement annuel, tandis que la perte d'exploitation s'est améliorée de 22%. La société disposait d'une trésorerie de $6 millions, renforcée par une levée de fonds en actions de $5 millions. NeurAxis a étendu sa population couverte à 53 millions de personnes et a obtenu un nouveau code CPT de Catégorie I pour les procédures PENFS, applicable à partir de janvier 2026. La société s'attend à atteindre le seuil de rentabilité en 2026.
NeurAxis (NYSE American: NRXS) meldete starke Finanzergebnisse für das 2. Quartal 2025: Die Umsätze stiegen um 46% gegenüber dem Vorjahr auf $894.000. Das Medizintechnikunternehmen, das sich auf Neuromodulations‑Therapien konzentriert, erreichte wichtige Meilensteine, darunter die FDA‑Zulassung für die erweiterte pädiatrische Behandlung und eine Empfehlung in den Leitlinien wissenschaftlicher Fachgesellschaften für seine PENFS‑Technologie.
Die Betriebskosten gingen um 10% im Jahresvergleich zurück, während der operative Verlust sich um 22% verbesserte. Das Unternehmen verfügte über einen Kassenbestand von $6 Millionen, gestützt durch eine Eigenkapitalfinanzierung in Höhe von $5 Millionen. NeurAxis weitete die abgedeckte Personenzahl auf 53 Millionen aus und erhielt einen neuen Category‑I‑CPT‑Code für PENFS‑Verfahren, gültig ab Januar 2026. Das Unternehmen erwartet, 2026 die Gewinnschwelle zu erreichen.
- Revenue growth of 46% year-over-year to $894,000
- Operating expenses reduced by 10% compared to Q2 2024
- Operating loss improved by 22% year-over-year
- Secured $5 million equity financing from institutional investors
- Expanded insurance coverage to 53 million covered lives
- Received new Category I CPT code for PENFS procedures
- FDA clearance for expanded pediatric treatment age range (8-21 years)
- Unit sales increased 58% year-over-year
- Gross margin declined to 83.6% from 88.0% year-over-year
- Cash used in operations increased by $124,000 compared to prior year
- Higher inventory purchases impacting cash flow
- Net loss of $1.7 million despite improvements
Insights
NeurAxis shows strong momentum with 46% revenue growth and regulatory wins, but still operating at a loss with breakeven expected in 2026.
NeurAxis delivered an impressive
The financial picture shows a company executing a classic medical device commercialization strategy: building insurance coverage while managing cash burn. Their
Two metrics deserve particular attention. First, gross margins declined to
The January 2026 implementation of a Category I CPT code represents a crucial inflection point for revenue growth and gross margin improvement. This coding change typically leads to broader insurance adoption and more consistent reimbursement rates. Combined with their expanded FDA clearances for pediatric Functional Dyspepsia and the wider age range (8-21 years versus previous 11-18 years), NeurAxis has substantially increased its addressable market while establishing strong reimbursement infrastructure.
The coverage expansion to approximately 53 million covered lives represents significant progress, though still leaves substantial room for growth in a U.S. market of over 300 million insured lives. The recommendation in pediatric guidelines for Functional Abdominal Pain should accelerate this coverage expansion, as clinical guidelines often drive payer decisions.
Conference call will be held today, Tuesday, August 12 at 9:00 am ET
CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025.
2Q25 Financial highlights
- Revenues increased
46% year over year to$894 thousand in 2Q25 compared to$612 thousand in 2Q24. - Operating expenses decreased
10% year over year in 2Q25 compared to 2Q24. - Operating loss improved by
22% compared to the second quarter of 2024. - Cash balance was
$6 million as of June 30, 2025. The Company secured$5 million through an equity-only financing round, with participation by existing and new institutional investors.
Recent Operational Highlights
- Secured key academic society guidelines recommendation for treatment of Functional Abdominal Pain (FAP) in IBS. NeurAxis’s PENFS technology is the only FDA-cleared or approved treatment that is recommended in the pediatrics guidelines, enabling momentum for large-scale insurance coverage for IB-Stim.
- Awarded first ever FDA Clearance for the treatment of pediatric FAP/Functional Dyspepsia (FD) and associated nausea symptoms, significantly expanding IB-Stim’s total addressable market.
- Expanded total covered lives to approximately 53 million.
- Assignment of a new Current Procedural Terminology Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures. This code is effective for utilization on January 1, 2026 and includes RVUs & financials for reimbursement.
- Received new FDA clearance for the expansion of IB-Stim label:
- to allow for a larger patient population beyond 11-18 years of age to 8-21 years.
- to increase devices per patient to 4 devices.
- Received 510(k) clearance from the FDA for its rectal expulsion device (RED) product. RED’s innovative design simplifies anorectal function testing in adult patients with chronic constipation and can be used without interrupting clinical workflow.
Management Commentary
Brian Carrico, CEO of NeurAxis commented “We remain highly encouraged by the Company’s trajectory, with strong revenue growth anticipated in the near term following several critical achievements in recent months. Our focus continues to be on expanding insurance coverage and executing large-scale IB-Stim commercialization.
In May, we completed a
We are approaching a major inflection point with national insurance coverage, as IB-Stim’s Category I CPT code is set for utilization on January 1, 2026. Additionally, we recently secured inclusion of our proprietary PENFS technology in clinical practice guidelines from leading academic societies—a significant endorsement that supports expanded access on a broader scale. We expect this expanded coverage to drive substantial revenue growth and improved gross margins, as more devices are reimbursed at full commercial rates.
We also achieved a major regulatory milestone with FDA clearance to expand IB-Stim’s indication to include pediatric Functional Dyspepsia. This expansion significantly increases our total addressable market and enables us to leverage our existing provider and payer relationships.
Operational performance remained strong in the second quarter, with revenue increasing
Second Quarter 2025 Financial Results
Revenues in the second quarter of 2025 were
Gross margin in the second quarter of 2025 declined to
Operating expenses in the second quarter of 2025 were
Operating loss in the second quarter of 2025 was
Net loss in the second quarter of 2025 was
Cash on hand as of June 30, 2025, was
Conference Call Details
Date and Time: Tuesday, August 12, 2025, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/8yd7cjue. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following Call In Link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/8yd7cjue.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA-cleared for Functional Abdominal Pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia and associated Nausea Symptoms in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For contraindications, precaution, warnings, and IFU, please see: https://ibstim.com/important-information/.
For important RED information, including indications, precautions, and contraindications, visit: https://red4constipation.com/information/
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
| NeurAxis, Inc. Condensed Statements of Operations (Unaudited) | |||||||||||||||
| (Unaudited) | (Unaudited) | ||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net sales | $ | 894,086 | $ | 611,500 | $ | 1,789,741 | $ | 1,258,135 | |||||||
| Cost of goods sold | 146,643 | 73,458 | 286,118 | 148,539 | |||||||||||
| Gross profit | 747,443 | 538,042 | 1,503,623 | 1,109,596 | |||||||||||
| Selling expenses | 142,253 | 62,274 | 276,206 | 142,304 | |||||||||||
| Research and development | 58,319 | 54,312 | 108,012 | 59,882 | |||||||||||
| General and administrative | 2,264,729 | 2,628,288 | 5,132,360 | 4,946,362 | |||||||||||
| Operating loss | (1,717,858 | ) | (2,206,832 | ) | (4,012,955 | ) | (4,038,952 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Financing charges | - | - | - | (230,824 | ) | ||||||||||
| Interest expense, net | (13,434 | ) | (80,697 | ) | (15,672 | ) | (107,257 | ) | |||||||
| Change in fair value of warrant liability | (119 | ) | 7,576 | 1,712 | (1,708 | ) | |||||||||
| Amortization of debt discount and issuance costs | - | (63,817 | ) | - | (85,500 | ) | |||||||||
| Other income | 40,993 | 2,961 | 57,813 | 2,961 | |||||||||||
| Other expense | - | (576,901 | ) | - | (577,081 | ) | |||||||||
| Total other income (expense), net | 27,440 | (710,878 | ) | 43,853 | (999,409 | ) | |||||||||
| Net loss | $ | (1,690,418 | ) | $ | (2,917,710 | ) | $ | (3,969,102 | ) | $ | (5,038,361 | ) | |||
FAQ
What were NeurAxis (NRXS) Q2 2025 earnings results?
What new FDA clearances did NeurAxis receive in 2025?
When will NeurAxis's new CPT code become effective?
How many covered lives does NeurAxis now have for insurance?
What is NeurAxis's current cash position and recent financing?
When does NeurAxis expect to reach breakeven?
